Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orally inhaled apomorphine in Parkinson's disease
ISRCTN41929673Phase 2Completed
- Sponsor
- Vectura
- Start
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Orally inhaled apomorphine HCl with Placebo (2 arms). Primary endpoints: Change in off time per day and Maximum change in total UPDRS III score. Started Jan 2009; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN41929673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41929673.